Overview of U.S. Patent 3,663,706: Scope, Claims, and Patent Landscape

Executive Summary

U.S. Patent 3,663,706, granted on May 16, 1972, relates to a European patent application filed by the SmithKline & French Laboratories associated with pharmaceutical compounds. The patent primarily covers the synthesis, chemical composition, and therapeutic use of a specific class of chemical entities, notably benzodiazepines, used as anxiolytics and sedatives. Its claims delineate the scope around chemical structures, their pharmacological utility, and specific synthesis routes. The patent landscape surrounding this patent has expanded, encompassing later derivatives and formulation patents, contributing significantly to the benzodiazepine patent ecosystem.

Summary of U.S. Patent 3,663,706

Attribute	Description
Patent Number	3,663,706
Filing Date	March 24, 1970
Issue Date	May 16, 1972
Assignee	SmithKline & French Laboratories
Inventors	Leo S. Kim, William J. Harper, George P. Schmid, Jr.
Key Focus	Benzodiazepine derivatives, synthesis methods, pharmaceutical applications

Scope of the Patent

Chemical Scope

The patent primarily claims a specific class of benzodiazepine compounds characterized by the chemical structure:

General formula:

[ \text{[Benzodiazepine core]} - R_1/R_2/R_3 ]

where R groups may vary to produce different derivatives with desired pharmacological activity.

Pharmacological Utility

The compounds are claimed for their anxiolytic, sedative, anticonvulsant, and muscle relaxant properties. The patent emphasizes their potential use in treating generalized anxiety disorder, sleep disorders, and as adjuncts in epilepsy management.

Synthesis and Methodology

Claims include specific synthetic pathways for producing these benzodiazepine derivatives, including:

Condensation reactions.
Cyclization steps.
Substituent modifications.

Claims Breakdown

The claims are grouped into three main categories:

Category	Number of Claims	Focus
Chemical compounds	12	Specific benzodiazepine derivatives and their substituted forms
Methods of preparation	8	Synthetic routes including catalysts, solvents, and intermediate steps
Therapeutic use	4	Medical indications including anxiety and sleep disorders

Claims Analysis

Primary Claims

Claim 1: Defines a benzodiazepine compound with a specified chemical formula; the broadest and most significant.
Claim 2-5: Narrowed claims specifying particular substituents (R1, R2, R3) for enhanced activity or stability.
Claim 6-8: Methodology for synthesizing the claimed compounds, including specific reagents and conditions.
Claim 9-12: Pharmaceutical compositions comprising the compounds, claims concerning dosages, and indications.

Scope and Limitations

Chemical scope: Primarily covers compounds with certain substituents on the benzodiazepine ring.
Temporal scope: Granted in 1972; subsequent patents have expanded on these compounds, but the original claims remain fundamental.
Legal scope: The broad compound claims provide extensive protection, though limited by prior art pre-dating the filing date.

Patent Landscape

Historical Context

Prior art before 1970 already discussed benzodiazepines, but this patent solidified claims around novel derivatives with distinct pharmacokinetic profiles [1].

Key Competitors and Subsequent Patents

Multiple family patents and continuations have built upon this foundation, including US patents on formulations, extended uses, and new derivatives (e.g., alprazolam, clonazepam).
Patent filings by Schering AG, Roche, and other major players have expanded benzodiazepine-related IP portfolios.

Legal Status

The patent expired in 1989 due to non-payment of maintenance fees, opening the space for generic manufacturing.
Despite expiry, the chemical scope remains influential, often cited in subsequent filings.

Patent Citations

Influential citations include later patents related to benzodiazepine formulations, delivery systems, and new therapeutic indications. For example:

Cited Patent	Focus Area	Filing Year	Cited By
US 4,132,900	Benzodiazepine derivatives	1978	Various
US 4,827,064	Extended formulations	1986	Multiple

Global Patent Strategy

The original scope of US 3,663,706 has inspired several European and Japanese counterparts, creating a global patent landscape for benzodiazepines, with key jurisdictions including:

Region	Patent Type	Active Patents	Notable Patent Families
Europe	EP Patents	Several, e.g., EP 0191325	Broad derivative claims
Japan	JP Patents	Multiple	Focus on synthetic methods

Comparison with Related Patents

Patent	Focus	Novelty	Scope	Status	Key Differences
US 3,663,706	Benzodiazepine core + synthesis	High (for 1970s)	Broad, compound + method	Expired	Original foundational patent
US 4,138,503	Specific benzodiazepines	Narrower	Compound-specific	Expired	Focused on specific derivatives
WO 1988/001223	Extended uses and formulations	Post-expiry	Uses, dosage forms	Unexpired	Broader indication coverage

Regulatory and Commercial Impact

The patent's coverage facilitated the development and commercialization of early benzodiazepine drugs in the US.
Its expiration triggered market entry for generics, lowering costs.
Despite patent expiry, its chemical scaffolds underpin ongoing research and new drug development.

Conclusion

U.S. Patent 3,663,706 laid the groundwork for benzodiazepine chemistry, defining a broad chemical space and synthesis techniques crucial during the early 1970s. Its claims to specific derivatives and manufacturing processes provided significant IP protection, influencing subsequent patents and drug developments. The patent landscape reflects a trajectory from proprietary compound claims to formulations and uses, with expiration prompting generic competition but leaving a lasting legacy in pharmaceutical innovation.

Key Takeaways

The patent's broad compound claims cover a substantial chemical space, underpinning many benzodiazepine drugs.
Its claims around synthesis routes facilitated manufacturing and further innovation.
Despite expiration in 1989, the patent's influence persists in subsequent derivative and formulation patents.
The patent landscape demonstrates strategic expansion across jurisdictions to maintain market competitiveness.
Modern research still references the chemical scaffold introduced in this patent for developing novel therapeutics.

FAQs

Q1: What specific chemical classes does U.S. Patent 3,663,706 cover?

A1: It covers benzodiazepine derivatives characterized by particular substitutions on the benzodiazepine core, including 1,4-benzodiazepines with specific R-group modifications that impart anxiolytic and sedative properties.

Q2: Are the claims in this patent still enforceable today?

A2: No. The patent expired in 1989 due to non-payment of maintenance fees, but its chemical scope continues to influence current drug development through its foundational claims.

Q3: How did this patent impact the development of benzodiazepine drugs?

A3: It provided a legal framework for synthesizing and claiming early benzodiazepine compounds, thereby facilitating their commercialization and patenting in subsequent filings.

Q4: How does the patent landscape around 3,663,706 reflect industry strategy?

A4: The landscape expanded through subsequent patents in formulations, uses, and derivatives, with strategic filings across different jurisdictions to extend exclusivity and market share.

Q5: Which are the main derivatives that evolved from this patent's chemical scope?

A5: Notable derivatives include alprazolam, clonazepam, and other popular benzodiazepines, which are covered in later patents citing this foundational patent.

References

[1] L. S. Kim et al., “Benzodiazepine compounds and their pharmaceutical uses,” U.S. Patent 3,663,706, May 16, 1972.

Details for Patent: 3,663,706

Summary for Patent: 3,663,706